Ipsen has introduced corabotase, the first molecule in a new class of recombinant neuroinhibitors, designed to treat moderate to severe upper facial lines such as glabellar lines. Phase II trial data presented at the SCALE Symposium showed corabotase's rapid onset and sustained effect, with ongoing studies expanding to forehead and lateral canthal lines. This innovative treatment uses advanced protein engineering to enhance efficacy and durability. Ipsen plans further clinical development to confirm its benefits across multiple aesthetic indications.
Ipsen has introduced corabotase, the first molecule in a new class of recombinant neuro-inhibitors, at the SCALE symposium. Phase II trial data show corabotase's safety and efficacy in treating moderate to severe facial wrinkles, including glabellar ...
Eight Directions Technology Limited, a provider of premium customized disposable products, has agreed to merge with Quartzsea Acquisition Corporation, a special purpose acquisition company (SPAC). The merger will result in Eight Directions becoming a...
DeFi Development Corp. reported a 108% increase in fully converted SOL per share over the past year, reaching 0.0670 by May 13. Despite this growth, the company posted a significant $83.4 million net loss in Q1 2026, driven by lower SOL prices impact...
Whirlpool's shares have fallen 45% year-to-date due to collapsing demand, shrinking profit margins, and significant balance sheet stress. The company's Q1 results showed a surprise loss, a sharp decline in EBIT margin to 1.3%, and major cuts to earni...
Trump Mobile announced that its delayed T1 smartphone will start shipping next week, but the TRUMP memecoin fell 5% following the news. The phone faces skepticism due to shipment delays, limited support, and doubts about its manufacturing, with repor...
